-
Ferrier Research Institute and BCFNZ to create new breast cancer vaccine
pharmaceutical-technology
March 23, 2017
Victoria University of Wellington's Ferrier Research Institute and the Breast Cancer Foundation New Zealand (BCFNZ) ...
-
Pierre Fabre and H-Immune to develop new cancer immunotherapies
pharmaceutical-technology
March 23, 2017
French pharmaceutical company Pierre Fabre and H-Immune have entered a strategic research partnership to develop ...
-
BMS, CytomX Expand Probody Pact
contractpharma
March 21, 2017
BMS gains worldwide rights to develop and commercialize as many as six additional oncology targets
-
NICE rejects use of daratumumab (darzalex) monotherapy for treatment of myeloma
pharmaceutical-technology
March 21, 2017
he UK National Institute for Health and Care Excellence (NICE) has issued draft negative guidance on anti-cancer drug...
-
Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ The
americanpharmaceuticalreview
March 21, 2017
Bristol-Myers Squibb Company and CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer...
-
Crown Bioscience Appoints GM
contractpharma
March 20, 2017
Thatte to head up the company's center of excellence in San Diego
-
Threshold Pharmaceuticals and Molecular Templates Agree to Combine
americanpharmaceuticalreview
March 20, 2017
The transaction will result in a combined company focused on the development of novel treatments for cancer.
-
AZ’ Lynparza hits targets in ovarian cancer trial
pharmatimes
March 17, 2017
AstraZeneca has unveiled data from a late-stage trial showing that Lynparza improved progression free survival (PFS) in ...
-
Angsana’s RNA-based fusions cancer panel selected for Ignyta’s STARTRK2 clinical trial in Asia-Pacif
pharmaasia
March 16, 2017
Angsana Molecular & Diagnostics to partner with molecular test laboratory for STARTRK-2 clinical trial sites in Asia working with Ignyta.
-
US nod for Novartis’ breast cancer drug Kisqali
pharmatimes
March 15, 2017
Novartis’ selective cyclin-dependent kinase inhibitor Kisqali has been approved by the US Food and Drug Administration...
ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
